JP5162812B2 - Zinc-containing composition for oral administration - Google Patents

Zinc-containing composition for oral administration Download PDF

Info

Publication number
JP5162812B2
JP5162812B2 JP2005196924A JP2005196924A JP5162812B2 JP 5162812 B2 JP5162812 B2 JP 5162812B2 JP 2005196924 A JP2005196924 A JP 2005196924A JP 2005196924 A JP2005196924 A JP 2005196924A JP 5162812 B2 JP5162812 B2 JP 5162812B2
Authority
JP
Japan
Prior art keywords
zinc
acid
oral administration
solution
purified water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2005196924A
Other languages
Japanese (ja)
Other versions
JP2006045216A (en
Inventor
拓人 武井
和夫 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP2005196924A priority Critical patent/JP5162812B2/en
Publication of JP2006045216A publication Critical patent/JP2006045216A/en
Application granted granted Critical
Publication of JP5162812B2 publication Critical patent/JP5162812B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicinal Preparation (AREA)

Description

本発明は、亜鉛化合物の不快な味を低減し、服用感を良好にした経口投与用組成物に関する。   The present invention relates to a composition for oral administration in which an unpleasant taste of a zinc compound is reduced and a feeling of taking is improved.

亜鉛化合物は亜鉛イオンに由来する不快な味のため飲みにくいものであった。この味は、タンニンやミョウバンなどのタンパクと結合する収斂剤を口にしたときの味(収斂味)と共通のものである。これまで、収斂味を有する化合物を含有する組成物の不快な味を改善するため、ゼラチン等のタンパク質を配合する技術が開示されている(特許文献1)。しかしながら、ゼラチンでは冷却時にゲル化するため、配合量および加工適性の制約を余儀なくされ、特に低粘性の内服液剤には利用しにくい等の問題があった。   Zinc compounds are difficult to drink due to an unpleasant taste derived from zinc ions. This taste is the same as the taste when using an astringent that binds to proteins such as tannin and alum (astringent taste). Until now, in order to improve the unpleasant taste of a composition containing a compound having an astringent taste, a technique of blending a protein such as gelatin has been disclosed (Patent Document 1). However, since gelatin gels upon cooling, there are inevitably restrictions on the blending amount and processability, and there is a problem that it is difficult to use especially for low-viscosity oral liquids.

特開昭57−171909号公報Japanese Patent Laid-Open No. 57-171909

本発明は、亜鉛イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない亜鉛含有経口投与用組成物を提供することである。   An object of the present invention is to provide a composition for oral administration containing zinc that reduces the astringent taste derived from zinc ions, is easy to drink, and does not leave an unpleasant aftertaste.

本発明者らは、上記課題を解決するために鋭意検討を重ねた結果、亜鉛化合物を含有する経口投与用組成物において、コラーゲンペプチド、植物性ペプチドを配合すると亜鉛イオンによるタンパクの凝集(収斂性)が低減し、収斂味が改善されることを見出し、本発明を完成するに至った。すなわち、本発明は、亜鉛化合物にペプチドを配合した経口投与用組成物である。   As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that, in a composition for oral administration containing a zinc compound, when a collagen peptide or a vegetable peptide is added, protein aggregation by zinc ions (convergence) ) Is reduced and the astringency is improved, and the present invention has been completed. That is, this invention is a composition for oral administration which mix | blended the peptide with the zinc compound.

本発明における亜鉛化合物とは、亜鉛を含む塩であり、塩を形成する酸が無毒性であれば有機酸又は無機酸のどちらでもかまわず、有機酸としては例えば、乳酸、グルコン酸、クエン酸、リンゴ酸、酒石酸等の有機酸を、また無機酸としては、例えば、硫酸、炭酸、塩酸、リン酸、硝酸等を挙げることができる。好ましい亜鉛化合物としてはグルコン酸亜鉛、硫酸亜鉛、クエン酸亜鉛、炭酸亜鉛、塩化亜鉛およびリン酸亜鉛などが挙げられる。これらは、単独で配合してもよく、2種以上を組み合わせて配合してもよい。   The zinc compound in the present invention is a salt containing zinc. If the acid forming the salt is non-toxic, either an organic acid or an inorganic acid may be used. Examples of the organic acid include lactic acid, gluconic acid, and citric acid. Organic acids such as malic acid and tartaric acid, and inorganic acids include sulfuric acid, carbonic acid, hydrochloric acid, phosphoric acid, nitric acid and the like. Preferred zinc compounds include zinc gluconate, zinc sulfate, zinc citrate, zinc carbonate, zinc chloride and zinc phosphate. These may be blended singly or in combination of two or more.

亜鉛化合物の配合量はその使用目的により異なるが、栄養摂取量の面からは、亜鉛イオンに換算して、1日当たり1〜50mgが好ましい。なお、1日に100mlの飲料として摂取する場合には、その亜鉛イオン濃度は0.001〜0.05W/V%である。   Although the compounding quantity of a zinc compound changes with the intended purposes, from the surface of nutrient intake, 1-50 mg per day is preferable in conversion to a zinc ion. In addition, when ingesting as a 100 ml drink a day, the zinc ion density | concentration is 0.001-0.05 W / V%.

本発明におけるペプチドとは、タンパク質を酵素あるいは酸で分解させ、タンパク質の機能を向上あるいは新機能を付加させたもので、基質となるタンパク質の種類、酵素の選択、分解、精製方法などにより様々な機能のものがある。このようなタンパク質分解物の中でも特に畜肉又は魚肉由来のコラーゲンペプチド、とうもろこし由来の植物性ペプチドが好ましい。   The peptide in the present invention is a protein that is decomposed with an enzyme or an acid to improve the function of the protein or add a new function. There are functional ones. Among such protein degradation products, collagen peptides derived from livestock meat or fish meat, and plant peptides derived from corn are particularly preferred.

本発明の経口投与用組成物において、亜鉛イオンとペプチドの配合比は、亜鉛イオン1重量部に対して通常0.1重量部以上であり、好ましくは0.5〜6000重量部であり、より好ましくは2.5〜2000重量部である。   In the composition for oral administration of the present invention, the compounding ratio of zinc ions and peptides is usually 0.1 parts by weight or more, preferably 0.5 to 6000 parts by weight with respect to 1 part by weight of zinc ions. Preferably it is 2.5-2000 weight part.

本発明の亜鉛含有経口投与用組成物を内服液剤とする場合には、防腐性および風味等を考慮してそのpHを2.5〜7.0、好ましくは3.0〜5.5とする。この内服液剤のpHは、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸、コハク酸などの有機酸およびその塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を添加して調整できる。   When the zinc-containing composition for oral administration of the present invention is used as an internal solution, the pH is adjusted to 2.5 to 7.0, preferably 3.0 to 5.5 in consideration of antiseptic properties and flavor. . For example, citric acid, malic acid, fumaric acid, tartaric acid, lactic acid, succinic acid, and other organic acids and salts thereof, phosphoric acid, hydrochloric acid, and other inorganic acids, and inorganic bases such as sodium hydroxide are added. Can be adjusted.

本発明の亜鉛含有経口投与用組成物には、ビタミン類、ミネラル類、アミノ酸類、生薬、生薬抽出物、カフェイン、ローヤルゼリーなどを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、保存剤、甘味料などの添加物を本発明の効果を損なわない範囲で適宜に配合できる。   Vitamins, minerals, amino acids, herbal medicines, herbal extracts, caffeine, royal jelly, and the like can be appropriately added to the zinc-containing composition for oral administration of the present invention as long as the effects of the present invention are not impaired. Moreover, additives such as antioxidants, colorants, flavors, flavoring agents, surfactants, solubilizers, preservatives, sweeteners, and the like can be appropriately blended as necessary so long as the effects of the present invention are not impaired.

本発明の亜鉛含有経口投与用組成物を調製する方法は特に限定されるものではない。内服液剤とする場合には、通常、各成分を適量の精製水で溶解した後、pHを調整し、残りの精製水を加えて容量調整し、必要に応じて濾過、滅菌処理することにより目的の亜鉛含有経口投与用組成物が得られる。   The method for preparing the zinc-containing composition for oral administration of the present invention is not particularly limited. When using it as an internal solution, the purpose is usually to dissolve each component with an appropriate amount of purified water, adjust the pH, adjust the volume by adding the remaining purified water, and filter and sterilize as necessary. A zinc-containing composition for oral administration is obtained.

以下に実施例及び試験例を挙げ、本発明をより詳しく説明する。   Hereinafter, the present invention will be described in more detail with reference to examples and test examples.

実施例1
グルコン酸亜鉛 0.04g
コーンペプチド 1.00g
ポリグリセリン脂肪酸エステル 0.20g
酢酸トコフェロール 0.10g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
アミノエチルスルホン酸 2.00g
キシリトール 4.00g
トレハロース 5.00g
エリスリトール 5.00g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
グリセリン 0.20g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.0に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 1
Zinc gluconate 0.04g
Corn peptide 1.00g
Polyglycerol fatty acid ester 0.20 g
Tocopherol acetate 0.10g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 2.00g
Xylitol 4.00g
Trehalose 5.00g
Erythritol 5.00g
Citric acid 0.80 g
Sodium citrate
Sodium benzoate 0.06g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例2
グルコン酸亜鉛 0.08g
コラーゲンペプチド 1.00g
グルコン酸カルシウム 2.00g
アスパラギン酸マグネシウム 1.00g
硝酸チアミン 0.01g
リボフラビン 0.01g
塩酸ピリドキシン 0.10g
アスコルビン酸 1.00g
アミノエチルスルホン酸 1.00g
ソルビトール 4.00g
トレハロース 5.00g
キシリトール 4.00g
ステビア抽出物 0.03g
アセスルファムカリウム 0.03g
リンゴ酸 0.10g
クエン酸 0.40g
クエン酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
アップルフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.0に調整し、精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 2
Zinc gluconate 0.08g
Collagen peptide 1.00g
Calcium gluconate 2.00g
Magnesium aspartate 1.00 g
0.01 g of thiamine nitrate
Riboflavin 0.01g
0.10 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 1.00g
Sorbitol 4.00g
Trehalose 5.00g
Xylitol 4.00g
Stevia extract 0.03g
Acesulfame potassium 0.03g
Malic acid 0.10g
Citric acid 0.40g
Sodium citrate
Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Apple flavor 0.10g
After dissolving the above components in purified water, the pH was adjusted to 4.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例3
グルコン酸亜鉛 0.08g
コーンペプチド 0.50g
ポリグリセリン脂肪酸エステル 0.20g
ポリオキシエチレン硬化ヒマシ油 0.10g
トリカプリリン 0.05g
グルコン酸カルシウム 0.80g
アスパラギン酸マグネシウム 0.40g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
ニコチン酸アミド 0.10g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
塩化カルニチン 0.20g
アルギニン塩酸塩 0.20g
ヨクイニン流エキス 2.00mL
ブドウ糖 5.00g
難消化性デキストリン 4.00g
エリスリトール 5.00g
キシリトール 2.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
スクラロース 0.05g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
グリセリン 0.20g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 3
Zinc gluconate 0.08g
Corn peptide 0.50g
Polyglycerol fatty acid ester 0.20 g
Polyoxyethylene hydrogenated castor oil 0.10g
Tricaprylin 0.05g
Calcium gluconate 0.80 g
Magnesium aspartate 0.40 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Nicotinamide 0.10g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Carnitine chloride 0.20g
Arginine hydrochloride 0.20g
Yokuinin style extract 2.00mL
Glucose 5.00g
Indigestible dextrin 4.00 g
Erythritol 5.00g
Xylitol 2.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Sucralose 0.05g
Citric acid 0.80 g
Sodium citrate
Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

実施例4
グルコン酸亜鉛 0.01g
コーンペプチド 0.30g
ポリグリセリン脂肪酸エステル 0.20g
ポリオキシエチレン硬化ヒマシ油 0.10g
トリカプリリン 0.05g
乳酸カルシウム 0.30g
塩化マグネシウム 0.06g
クエン酸鉄アンモニウム 0.04g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.02g
塩酸ピリドキシン 0.03g
ニコチン酸アミド 0.05g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ローヤルゼリー 0.60g
ブドウ糖 5.00g
ソルビトール 5.00g
キシリトール 5.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
クエン酸 0.80g
クエン酸ナトリウム 0.10g
リン酸 0.30g
塩酸 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
グリセリン 0.20g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 4
Zinc gluconate 0.01g
Corn peptide 0.30g
Polyglycerol fatty acid ester 0.20 g
Polyoxyethylene hydrogenated castor oil 0.10g
Tricaprylin 0.05g
Calcium lactate 0.30g
Magnesium chloride 0.06g
0.04 g of ammonium iron citrate
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.02g
0.03 g of pyridoxine hydrochloride
Nicotinamide 0.05g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Royal jelly 0.60g
Glucose 5.00g
Sorbitol 5.00g
Xylitol 5.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Citric acid 0.80 g
Sodium citrate 0.10g
Phosphoric acid 0.30 g
Hydrochloric acid
Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.

試験例
Hagermanらは、溶液中のタンパク(ウシ血清アルブミン:BSA)がタンニンにより凝集し、その沈澱量はタンニンの量に比例することを報告した(J.Agric.Food.Chem.,1978,Vol.26,809-812)。本発明者らは、亜鉛イオン溶液にBSA溶液を加えると、この溶液が懸濁し、吸光度が上昇すること、この吸光度の上昇が、亜鉛イオンの濃度に相関することを見出した。これは、ある物質を添加した亜鉛イオン溶液をBSA溶液に混合したときの吸光度が無添加の場合と比較して減少すると、その物質の添加により、タンパク−亜鉛イオン相互作用による凝集(収斂性)が減少したこと、すなわち収斂味が減少したことを意味すると考えられる。
Test example
Hagerman et al. Reported that protein (bovine serum albumin: BSA) in solution was aggregated by tannin, and the amount of precipitation was proportional to the amount of tannin ( J. Agric . Food . Chem ., 1978, Vol. 26 , 809) . -812). The present inventors have found that the addition of BSA solution to a zinc ion solution, the solution was suspended, the absorbance increases, increase in absorbance was found to correlate with the concentration of zinc ions. This is because, when the absorbance when a zinc ion solution containing a certain substance is mixed with a BSA solution decreases compared to the case where no addition is made, the addition of that substance causes aggregation due to protein-zinc ion interaction (convergence). Is considered to mean that the astringent taste has decreased.

試験方法
(1)BSA溶液の調製:BSA(Sigma Chemical Co.;fraction V,fatty acid free)10gを適量の精製水に溶解し、クエン酸100mgを加え、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。
(2)希釈液の調製:クエン酸100mgを適量の水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。
(3)亜鉛イオン溶液の調製:グルコン酸亜鉛0.04g、0.19gおよび0.39gにクエン酸0.10gを加えた。それぞれを適量の精製水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、精製水で100mLとした。
(4)タンパク−亜鉛イオン相互作用(収斂性)の評価
各亜鉛イオン溶液2mLにBSA溶液6mLを加え、希釈液でそれぞれ全量を10mLとした。これを40℃で30分間振とうした。石英セル(L=1cm)を使用し、分光光度計(日立製作所製:U−3300)により、各透明溶液では吸収されない波長である500nmにおける吸光度を測定した。結果を(図1)に示す。
Test method
(1) Preparation of BSA solution: 10 g of BSA (Sigma Chemical Co .; fraction V, fatty acid free) is dissolved in an appropriate amount of purified water, 100 mg of citric acid is added, and pH is adjusted to 4. with NaOH solution (1 mol / L). 8 and adjusted to 100 mL with purified water.
(2) Preparation of diluting solution: 100 mg of citric acid was dissolved in an appropriate amount of water, pH was adjusted to 4.8 with NaOH solution (1 mol / L), and purified water was adjusted to 100 mL.
(3) Preparation of zinc ion solution: To 0.04 g, 0.19 g and 0.39 g of zinc gluconate, 0.10 g of citric acid was added. Each was dissolved in an appropriate amount of purified water, adjusted to pH 4.8 with NaOH solution (1 mol / L), and made up to 100 mL with purified water.
(4) Evaluation of protein-zinc ion interaction (convergence)
6 mL of BSA solution was added to 2 mL of each zinc ion solution, and the total volume was adjusted to 10 mL with the diluent. This was shaken at 40 ° C. for 30 minutes. Using a quartz cell (L = 1 cm), the absorbance at 500 nm, which is a wavelength that is not absorbed by each transparent solution, was measured with a spectrophotometer (manufactured by Hitachi, Ltd .: U-3300). The results are shown in (FIG. 1).

次に、各種濃度の亜鉛イオン溶液と収斂味(官能評価)との相関を調べた。官能評価は、収斂味が強くて許容できない場合をB、許容することができる範囲をその収斂味の強さに応じてA4〜A1とし、収斂味を全く感じない場合をAとして評価を行った。その結果を図2に示す。図2より、吸光度が約0.4以下であれば、亜鉛イオン由来の収斂味が十分抑制されていると判断した。   Next, the correlation between various concentrations of zinc ion solution and astringency (sensory evaluation) was examined. The sensory evaluation was evaluated as B when the astringent taste was strong and unacceptable, A4 to A1 depending on the strength of the astringent taste, and A when the astringent taste was not felt at all. . The result is shown in FIG. From FIG. 2, it was determined that the astringent taste derived from zinc ions was sufficiently suppressed when the absorbance was about 0.4 or less.

(5)検体のタンパク凝集性
上記と同様の試験方法により、表1に示す処方のタンパク凝集性を評価した。
(5) Protein aggregation properties of specimens The protein aggregation properties of the formulations shown in Table 1 were evaluated by the same test method as described above.

Figure 0005162812
Figure 0005162812

表1より、ペプチドを配合した検体1および検体2の吸光度は、ペプチドを含有しない検体3よりも小さいことから、ペプチドの配合により、亜鉛イオンに由来する収斂味を低減できることが明らかとなった。   From Table 1, since the absorbance of the sample 1 and the sample 2 containing the peptide was smaller than that of the sample 3 not containing the peptide, it was revealed that the astringent taste derived from the zinc ions can be reduced by adding the peptide.

本発明により、亜鉛イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない亜鉛含有経口投与用組成物を提供することができた。この亜鉛含有経口投与用組成物は、例えば、シロップ剤、ドリンク剤などの医薬品や医薬部外品を含む各種製剤及び栄養機能食品などの各種飲料に適用できる。   According to the present invention, it is possible to provide a composition for oral administration containing zinc that reduces the astringent taste derived from zinc ions, is easy to drink, and does not leave an unpleasant aftertaste. This zinc-containing composition for oral administration can be applied, for example, to various preparations including pharmaceuticals such as syrups and drinks and quasi-drugs and various beverages such as nutritional functional foods.

タンパク凝集と亜鉛イオン濃度の相関性を示す。The correlation between protein aggregation and zinc ion concentration is shown. 亜鉛イオン溶液における亜鉛イオン濃度と収斂味を官能評価した結果の相関性を示す。The correlation of the result of having sensory-evaluated the zinc ion density | concentration and astringency taste in a zinc ion solution is shown.

Claims (2)

グルコン酸亜鉛、コラーゲンペプチドおよびコーンペプチドから選ばれる1種又は2種のペプチドを精製水で溶解した後、pHを調整し、残りの精製水を加えて、亜鉛イオン濃度が0.001〜0.05W/V%となるように調製した内服液剤であることを特徴とする経口投与用組成物。 After dissolving one or two kinds of peptides selected from zinc gluconate, collagen peptide and corn peptide with purified water, the pH is adjusted, the remaining purified water is added, and the zinc ion concentration is 0.001 to 0.00. A composition for oral administration, which is an internal liquid preparation prepared so as to have a concentration of 05 W / V% . pHが2.5〜7.0である請求項1に記載の経口投与用組成物。 The composition for oral administration according to claim 1, which has a pH of 2.5 to 7.0.
JP2005196924A 2004-07-08 2005-07-06 Zinc-containing composition for oral administration Active JP5162812B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005196924A JP5162812B2 (en) 2004-07-08 2005-07-06 Zinc-containing composition for oral administration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004201318 2004-07-08
JP2004201318 2004-07-08
JP2005196924A JP5162812B2 (en) 2004-07-08 2005-07-06 Zinc-containing composition for oral administration

Publications (2)

Publication Number Publication Date
JP2006045216A JP2006045216A (en) 2006-02-16
JP5162812B2 true JP5162812B2 (en) 2013-03-13

Family

ID=36024207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005196924A Active JP5162812B2 (en) 2004-07-08 2005-07-06 Zinc-containing composition for oral administration

Country Status (1)

Country Link
JP (1) JP5162812B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106509954A (en) * 2016-10-20 2017-03-22 完美(中国)有限公司 Preparation method of corn peptide tablets

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4815798B2 (en) * 2004-12-17 2011-11-16 大正製薬株式会社 Copper-containing composition for oral administration
JP4889782B2 (en) 2008-12-24 2012-03-07 株式会社マルハニチロ食品 Bioactive complex containing protamine and / or salt thereof and acidic polymer compound and use thereof
JP5636199B2 (en) * 2010-03-02 2014-12-03 三基商事株式会社 How to reduce Amla's astringency
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171909A (en) * 1981-04-15 1982-10-22 Lion Corp Composition for oral cavity
IT1214505B (en) * 1987-03-12 1990-01-18 Gentili Ist Spa PROCEDURE FOR THE PREPARATION OF COLLAGEN AND PRODUCTS SO OBTAINED.
US5059416A (en) * 1989-06-26 1991-10-22 Warner-Lambert Company Zinc compound delivery system with improved taste and texture
US4992259A (en) * 1990-01-03 1991-02-12 Johnson & Johnson Consumer Products, Inc. Stable oral composition of zinc
JP3379198B2 (en) * 1994-03-04 2003-02-17 明治製菓株式会社 Food and drink promoting mineral absorption
US5897891A (en) * 1996-11-18 1999-04-27 Godfrey; John C. Flavorful zinc compositions for oral use incorporating copper
JP2004045217A (en) * 2002-07-11 2004-02-12 Toyoda Mach Works Ltd Pressure sensor
JP4147404B2 (en) * 2002-09-27 2008-09-10 国立大学法人信州大学 Plasma volume increase promoter
JP4715078B2 (en) * 2003-04-16 2011-07-06 大正製薬株式会社 Liquid composition for internal use containing iron compounds
JP4929628B2 (en) * 2004-07-08 2012-05-09 大正製薬株式会社 Zinc-containing oral solution

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106509954A (en) * 2016-10-20 2017-03-22 完美(中国)有限公司 Preparation method of corn peptide tablets

Also Published As

Publication number Publication date
JP2006045216A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CA2158001C (en) Calcium fortified beverages
JP4726269B2 (en) Oral solution
CN102858192A (en) Protein recovery beverage
JP5162812B2 (en) Zinc-containing composition for oral administration
KR20020018675A (en) Method and Composition for Masking Mineral Taste
JP5586816B2 (en) Composition containing zinc compound
JP4929628B2 (en) Zinc-containing oral solution
JP4337308B2 (en) Liquid composition
JP5098198B2 (en) Copper compound composition
JP5044957B2 (en) Copper compound composition
JP5546089B2 (en) Composition containing zinc compound
JP5167594B2 (en) Composition for internal use liquid containing copper compound
US20080124439A1 (en) Nutritional supplement composition comprising creatine and method for making the same
JP4929629B2 (en) Zinc-containing composition for oral administration
JP4622006B2 (en) Iron compound-containing oral solution composition
JP2001346556A (en) Fruit acid-containing drink
JP5151083B2 (en) Oral composition
JP5398100B2 (en) Oral liquid composition containing iron compound
JP4940492B2 (en) Iron compound combination oral solution
JP5181486B2 (en) Oral composition containing zinc compound
JP4815798B2 (en) Copper-containing composition for oral administration
WO2013062015A1 (en) Sweet composition showing reduced bitterness of sweetener having bitter taste, method for reducing bitterness, and food, drink, drug or quasi drug having reduced bitterness
JP4403595B2 (en) Iron compound-containing oral solution composition
WO2014010332A1 (en) Beverage
JP5011776B2 (en) Copper compound composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080528

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121203

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5162812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151228

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250